Executive Management Team
Our leadership team creates, hones and maintains our company’s focus and commitment to excellence in everything we do. The tireless work of these individuals continues to drive our growth, success and shareholder value.
Learn more about the dynamic people leading the way for Anika Therapeutics.
President & Chief Executive Officer
Mr. Darling joined Anika as President in July 2017, bringing more than 20 years of extensive experience in executive management and leadership from publicly-traded, commercial-stage companies, including Abbott Laboratories, Baxter Healthcare, Smith & Nephew, CONMED, and Wyeth-Ayerst. Most recently, Mr. Darling held executive leadership positions with two small privately held orthopedic companies. Prior to these roles, Mr. Darling held senior level executive positions at CONMED Corporation, a global, publicly-held, diversified medical device company, as Global President of its wholly-owned subsidiary, Linvatec Corporation, and as Executive Vice President of Global Corporate Commercial Operations. At CONMED, Mr. Darling led five global business units with approximately $760 million in annual revenues and re-energized the organizational efforts in sales, marketing, R&D, and business development activities that allowed the company to expand its portfolio of product offerings to its customers. Mr. Darling oversaw the launch and commercialization of many key new products while at Linvatec including several new sports medicine technologies in the shoulder (Shoulder Restoration System, Y-Knot Shoulder Anchor line), along with new products in the knee and hip joints. Before joining CONMED, Mr. Darling was Senior Vice President and General Manager for the sports medicine and biologics business at Smith & Nephew, where he played an important role in defining a global strategy that propelled the company to a leadership position in the sports medicine field. While at Smith & Nephew, Mr. Darling and his team were pioneers in developing the Hip Arthroscopy space from a commercial perspective. Mr. Darling launched his career at Abbott Laboratories where he was involved in the commercialization efforts of many pharmaceutical products in the neuroscience, antimicrobial, cardiovascular, and HIV treatment space. While at Abbott Laboratories, he held management positions in sales and marketing before joining Wyeth-Ayerst Pharmaceuticals in roles of marketing for the pain and inflammation and women’s healthcare franchises. He later joined Baxter Healthcare as a Vice President of marketing and health systems. Mr. Darling holds a Bachelor of Arts in Political Science from Syracuse University.
Chief Financial Officer
On April 1, 2013, Sylvia Cheung was appointed as Chief Financial Officer. Ms. Cheung brings to Anika a substantial number of years of financial and general management experience. Prior to her current position, Sylvia was the Vice President of Strategic Processes; and previously, she served as the General Manager for the company’s Italian-based subsidiary, Anika S.r.l. She joined Anika as Controller in 2005. In addition to fulfilling wide-ranging financial responsibilities as Controller, Sylvia led the company’s integration of Anika S.r.l. subsequent to its acquisition in 2009.
Prior to Anika, she held a series of progressively responsible financial management positions at Transkaryotic Therapies, Inc. From 1995 to 2000, Sylvia worked for PricewaterhouseCoopers, LLP as an Audit Senior Associate.
Sylvia holds a bachelor of business administration degree in accounting from the University of Massachusetts in Amherst, a master’s degree in business administration from Boston University, and is a Certified Public Accountant (inactive).
Executive Vice President of Business Development and Strategic Planning
Jim Loerop joined Anika Therapeutics on July 8th, 2019 as the Company’s Executive Vice President of Business Development and Strategic Planning. Most recently, Mr. Loerop served as Chief Corporate Development Officer for Lupin Pharmaceuticals where he was a member of the company’s Executive Leadership Team and was responsible for global business development and corporate development activities. Prior to his work with Lupin, Jim held senior leadership roles at various companies in the pharmaceutical and life sciences industry, including at Alexion Pharmaceuticals as Senior Vice President of Global Business Development, GlaxoSmithKline as Vice President of North America Business Development, and Steifel Laboratories as Senior Vice President of Global Corporate Development prior to GSK’s acquisition of Stiefel.
Mr. Loerop holds a B.S. in Marketing from Western Michigan University.
Executive Vice President of Human Resources
Tom Finnerty joined Anika Therapeutics, Inc. as the Company’s Chief Human Resources Officer on October 30, 2017. Most recently, Tom was a strategic human capital consultant with Anika Therapeutics. Prior to his work at Anika, Tom was the Senior Vice President of Human Resources at Smith & Nephew where he was responsible for delivering value added programs, processes, and leadership in all areas of global human capital management to over 10,000 employees. Prior to his time at Smith & Nephew, Mr. Finnerty served as Executive Director of Human Resources at Novartis/Chiron Diagnostics. Tom launched his career in human resources at The Foxboro Company, a global enterprise focused on designing and manufacturing innovative process control products and systems.
Tom holds a Masters in Business Administration from Babson College, and a Bachelor of Science in Business from the University of Massachusetts.
Vice President of International Sales
James Chase joined Anika Therapeutics, Inc. as Vice President of International Sales on August 6, 2018. Most recently, Mr. Chase served as the Business Unit Director of the Sports Medicine Division of Smith & Nephew for the United Kingdom and Ireland. Prior to this role, Mr. Chase held several senior level leadership roles at Smith & Nephew, including General Manager UK/Ireland, Vice President Northern Europe, and Managing Director UK/Ireland. In these roles, he has successfully led large commercial teams generating revenue in excess of $300m.
James holds a B.E. in Electrical Engineering from Plymouth University (Honors), and an M.B.A. from The Open University.
Vice President of Human Resources
On March 24, 2014, Steven Cyr joined Anika Therapeutics Inc. as the Vice President of Human Resources. He is responsible for all of the global human capital activities and programs of the company. Steve comes to Anika from DENTSPLY International, formerly Astra Tech Inc.(Astra Zeneca) in Waltham, MA where he worked from 2006 to 2014. Steve served as Vice President, Human Resources DENTSPLY Implants Division (North America). He was responsible for leading and managing all aspects of HR for the Dental Implant and Urology divisions. The employee population included sales, marketing, operations, R&D, manufacturing, and G&A. Previously, Steve was employed by Sepracor Pharmaceuticals in Marlborough, MA as the Associate Director Human Resources, Client Services. In addition, he has worked as a consultant supporting HR initiatives at Monster Worldwide in Maynard and DePuy AcroMed Medical Devices in Raynham. Furthermore, he has held positions with StorageNetworks, Inc., The Avicon Group, Inc., i2 Technologies, Cambridge Technology Partners, TASC, and Wang Information Services Corp.
Steve has a B.S. from the University of Maine in Liberal Arts Psychology (Honors), and an M.A. in Industrial /Organizational Psychology (Honors) from the University of New Haven.
Vice President of Finance and Corporate Controller
Stephen Garbacz joined Anika Therapeutics, Inc. as Vice President of Finance and Corporate Controller on May 6th, 2019. Most recently, Mr. Garbacz served as Senior Vice President of Finance and Operations at Spero Therapeutics, where he successfully directed all aspects of finance and business operations. Prior to this role, Mr. Garbacz held several senior level finance leadership roles at Epizyme, Biogen, and Kraft Foods. Mr. Garbacz began his career at the Brookings Institute.
Stephen holds a B.S. in Economics from George Mason University, an M.B.A. from Stern Graduate School of Business (NYU), and is a Certified Public Account.
Vice President of U.S. Sales
Stephen Goldy joined Anika Therapeutics, Inc. as Vice President of U.S. Sales on May 13th, 2019. Most recently, Mr. Goldy served as a Regional Vice President and Director of Sales at ConMed Orthopedics, where he successfully led the turnaround of the entire Northeast Region, growing sales to $50 million and leading a team of close to 50 sales professionals. Prior to this role, Mr. Goldy held several senior level sales and finance leadership roles at Smith & Nephew, Creekridge Capital and BankBoston.
Stephen holds a B.S. in Criminal Justice from the University of Massachusetts, and an M.B.A. from the University of Massachusetts.
Vice President of Operations
Alexei Goraltchouk joined Anika Therapeutics, Inc. as Vice President of Operations on June 11, 2018. Most recently, Mr. Goraltchouk served as Vice President of Operations at Avedro, Inc. where he was responsible for managing all aspects of Clinical and Commercial Production, Technical Operations, Procurement, and Supply Chain Management for the organization. Prior to his work at Avedro, Alex held senior leadership roles in Operations, Supply Chain Management, and R&D for several firms including Allergan, Inc., Regeneron, Inc., and Biogen, Inc.
Mr. Goraltchouk holds a B.S. in Materials Engineering and an M.S. in Chemical Engineering from the University of Toronto, as well as an M.B.A. and M.S. in Finance from Indiana University. He is a Cornell Certified Six Sigma Black Belt and holds professional certifications from Stanford University (Genetics and Genomics), Massachusetts Institute of Technology (Supply Chain Management), and the Project Management Institute (Project Management Professional).
Vice President of Regulatory, Quality, and Clinical Affairs
Mira Leiwant joined Anika Therapeutics, Inc. as the Company’s Vice President of Regulatory and Clinical Affairs on October 1, 2019. Most recently, Mira was Vice President of Regulatory Affairs at BTG International where she was responsible for the leadership of Interventional Oncology Regulatory functions and activities within the organization. Prior to her work at BTG International, Mira was the Senior Director of Regulatory and Quality Engineering at Lifecell Corporation where she oversaw the development of and led all Regulatory and Quality teams for the organization. Mira has also held senior leadership roles at a number of other Medical Device, Life Sciences, and Pharmaceutical organizations including Quality Assurance at Svelte Medical Systems, Inc., Vascular Therapies, and Micell Technologies. Mira began her career at Cordis Corporation.
Mira holds a M.E. in Mechanical Engineering, Bioengineering option and a B.S. in Mechanical Engineering, Bioengineering option, both from Cornell University, and is a Regulatory Affairs Certification (RAC) holder.
Vice President of Clinical Affairs
Carol Pekar joined Anika Therapeutics, Inc. as the Company’s Vice President of Clinical Affairs on September 23, 2019. Most recently, Carol was Vice President of Regulatory, Quality, and Clinical Affairs at Keratin Biosciences, Inc., formerly Microchips Biotech, Inc., where she was responsible for all Regulatory, Quality, and Clinical functions and activities within the organization. Prior to her work at Keratin, Carol was the Vice President of Regulatory and Clinical Affairs at Anika Therapeutics, Inc. Carol has also held senior leadership roles at a number of other Medical Device, Life Sciences, and Pharmaceutical organizations including Abiomed, Inc. and Palomar Medical Technologies, Inc. where she oversaw the development of and led all Regulatory, Quality, and Clinical programs for the organization. Carol launched her career in clinical research at the Moston Medical Center.
Carol holds a B.S. in Chemistry from St. Bonaventure University, an M.B.A. from Babson College, a Graduate Certificate in Regulatory Affairs from Northeastern University, and a Certificate in Clinical Research from Boston University School of Medicine, and is a Regulatory Affairs Certification (RAC) holder.
Robert Richard, Ph.D.
Vice President of Research & Development
Robert Richard, Ph.D., joined Anika Therapeutics, Inc. as Vice President of Research and Development on March 18, 2019. Most recently, Dr. Richard served as Vice President of Research and Development at Hyalex Orthopaedics, where he was responsible for all aspects of product and process development as well as preclinical testing to support the development of a novel polymer technology that mimics cartilage. Prior to his work at Hyalex, Bob held leadership roles at C.R. Bard, Boston Scientific and Johnson & Johnson, where he led Research & Development organizations through numerous product development initiatives from the conceptual phase through commercialization. Dr. Richard is a named inventor on 38 U.S. patents and currently has 19 U.S. patent applications pending.
Dr. Richard holds a B.S. in Chemistry and a B.S. in Biology from the University of Massachusetts at Dartmouth, and a Ph.D. in Polymer Chemistry and Plastics Engineering from the University of Massachusetts at Lowell.
Charles Sherwood III
Vice President Corporate Legal Counsel
On January 1, 2018, Charles Sherwood III was appointed to the position of Vice President Corporate Legal Counsel. Charles provides leadership to Anika’s internal legal function and has wide-ranging responsibilities associated with guiding the company through the current legal and regulatory environment worldwide. Prior to his current position, Charles held progressively senior roles within Anika’s legal department, and he has been responsible for a number of corporate projects.
Charles holds a B.A. in Economics from Middlebury College and a J.D. from Vanderbilt University, and he is admitted to the Massachusetts Bar.